Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | PRKCA | P17252 | 2/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580771 | 1.00 | CDK2 (0.54) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6580776 | 1.00 | CDK2 (0.54) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6581704 | 0.93 | CDK2 (0.50) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6581694 | 0.93 | CDK2 (0.50) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL7086250 | 0.89 | CCNE2 (0.46) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6583731 | 0.89 | CCNE2 (0.46) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6585562 | 0.87 | GSK3B (0.56) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6585557 | 0.87 | GSK3B (0.56) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6583089 | 0.85 | GSK3B (0.64) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6583897 | 0.85 | GSK3B (0.64) | CDK2CCNE2CDK4CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | CDK2 102/4885CCNE2 1424/4885CDK4 368/4885 |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | CDK2 206/4885CCNE2 2037/4885CDK4 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.